Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03775200 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
A Phase 2 study, sponsored by COMPASS Pathways.
- Completed
- Registry status
- Phase 2
- Development phase
- 233
- Enrollment target
NCT03775200: Completed Phase 2 study, sponsored by COMPASS Pathways.
NCT03775200 is a Phase 2 study that has completed, run by COMPASS Pathways. The registered enrollment target is 233 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03775200, a Phase 2 study, has completed, sponsored by COMPASS Pathways.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 233 participants
- Enrollment target
Study Summary
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
Primary Outcome
MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity. Response \>= 50% decrease and remission \<= 10 total score.
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2021-09-27 |
| Phase | Phase 2 |
What the finished NCT03775200 record still lists
NCT03775200 is an interventional study that assigns participants to a tested intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% higher).
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT03775200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03775200 about?
NCT03775200 is a clinical study titled "The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression". The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
What is the current status of trial NCT03775200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 233 participants. The study started on 2019-03-01. Estimated completion is 2021-09-27.
What interventions are being tested in trial NCT03775200?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT03775200?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03775200's enrollment target sits among peer trials
233 256th of 2000 higher than 1,745 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06993844 · 233 participants · Phase 1
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- NCT07141706 · 233 participants · Phase 1
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI